Skip to main content
Top
Published in: Rheumatology International 5/2015

01-05-2015 | Original Article - Observational Research

Changing patterns of clinical severity and risk of mortality in granulomatosis with polyangiitis over four decades: the Russian experience

Authors: Pavel I. Novikov, Sergey V. Moiseev, Ekaterina I. Kuznetsova, Eugenia N. Semenkova, Nikolay A. Mukhin

Published in: Rheumatology International | Issue 5/2015

Login to get access

Abstract

The aim of our study was to study the changes in the clinical picture and outcomes of granulomatosis with polyangiitis (Wegener’s) (GPA) over 40 years. Two hundred and forty-two consecutive patients with GPA were distributed into retrospective (1970–2003) and prospective (2004–2012) cohorts. Anti-neutrophil cytoplasmic antibodies were present in 82.6 % of patients. In 78.0 % of patients, diagnosis was confirmed histologically. We compared the clinical features of GPA and the incidence of the major and minor relapses and mortality in the two cohorts. The majority of patients in both cohorts had generalized GPA that involved upper respiratory tract (retrospective 89.5 % vs prospective 82.85 %), kidneys (60.5 vs 50.8 %) and lungs (64.0 vs 52.3 %). The total duration of follow-up in the retrospective and prospective cohorts was 468 and 397 patients-years, respectively. In the prospective cohort, we found trend to lower incidence of relapses (54.2 vs 66.2 per 100 patient-year; p = ns; odds ratio 0.82; 95 % CI 0.53–1.21) and significantly lower mortality (4.3 vs 7.9 per 100 patient-year; p = 0.04; odds ratio 0.54; 95 % CI 0.31–0.94). The leading causes of death in the retrospective cohort were lung disease (37.8 %), complications of immunosuppressive treatment (35.1 %) and kidney failure (13.5 %). In the prospective cohort, patients rarely died from terminal uraemia and pulmonary complications (0.0 and 17.6 %) while the proportion of cardiovascular events and complications of the immunosuppression as the causes of death increased (29.4 and 47.1 %). Modern treatment apparently reduced the incidence of relapses and mortality and modified the causes of death in the GPA patients.
Literature
1.
go back to reference Mohammad AJ, Jacobsson LT, Westman KW, Sturfelt G, Segelmark M (2009) Incidence and survival rates in Wegener’s granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa. Rheumatology 48:1560–1565CrossRefPubMed Mohammad AJ, Jacobsson LT, Westman KW, Sturfelt G, Segelmark M (2009) Incidence and survival rates in Wegener’s granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa. Rheumatology 48:1560–1565CrossRefPubMed
2.
go back to reference Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F et al (2013) 2012 revised International Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum 65:1–11CrossRefPubMed Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F et al (2013) 2012 revised International Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum 65:1–11CrossRefPubMed
3.
go back to reference Fauci AS, Wolff SM (1973) Wegener’s granulomatosis: studies in eighteen patients and a review of the literature. Medicine 52:535–561CrossRefPubMed Fauci AS, Wolff SM (1973) Wegener’s granulomatosis: studies in eighteen patients and a review of the literature. Medicine 52:535–561CrossRefPubMed
4.
go back to reference Khan AR, Chapman PT, Stamp LK, Wells JE, O’Donnell JL (2012) Wegener’s granulomatosis: treatment and survival characteristics in a high-prevalence southern hemisphere region. Intern Med J 42:e23–e26CrossRefPubMed Khan AR, Chapman PT, Stamp LK, Wells JE, O’Donnell JL (2012) Wegener’s granulomatosis: treatment and survival characteristics in a high-prevalence southern hemisphere region. Intern Med J 42:e23–e26CrossRefPubMed
5.
go back to reference Walsh M, Flossmann O, Berden A, Westman K, Höglund P, Stegeman C, Jayne D, European Vasculitis Study Group (2012) Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 64:542–548CrossRefPubMed Walsh M, Flossmann O, Berden A, Westman K, Höglund P, Stegeman C, Jayne D, European Vasculitis Study Group (2012) Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 64:542–548CrossRefPubMed
6.
go back to reference Holle JU, Gross WL, Latza U, Nölle B, Ambrosch P, Heller M et al (2011) Improved outcome in 445 patients with Wegener’s granulomatosis in a German vasculitis center over four decades. Arthritis Rheum 63:257–266CrossRefPubMed Holle JU, Gross WL, Latza U, Nölle B, Ambrosch P, Heller M et al (2011) Improved outcome in 445 patients with Wegener’s granulomatosis in a German vasculitis center over four decades. Arthritis Rheum 63:257–266CrossRefPubMed
7.
go back to reference Takala JH, Kautiainen H, Malmberg H, Leirisalo-Repo M (2008) Wegener’s granulamatosis in Finland in 1981–2000: clinical presentation and diagnostic delay. Scand J Rheumatol 37:435–438CrossRefPubMed Takala JH, Kautiainen H, Malmberg H, Leirisalo-Repo M (2008) Wegener’s granulamatosis in Finland in 1981–2000: clinical presentation and diagnostic delay. Scand J Rheumatol 37:435–438CrossRefPubMed
8.
go back to reference Abdou NI, Kullman GJ, Hoffman GS, Sharp GC, Specks U, McDonald T et al (2002) Wegener’s granulomatosis: survey of 701 patients in North America. Changes in outcome in the 1990s. J Rheumatol 29:309–316PubMed Abdou NI, Kullman GJ, Hoffman GS, Sharp GC, Specks U, McDonald T et al (2002) Wegener’s granulomatosis: survey of 701 patients in North America. Changes in outcome in the 1990s. J Rheumatol 29:309–316PubMed
9.
go back to reference Guillevin L, Pagnoux C, Seror R, Mahr A, Mouthon L, Le Toumelin P, French Vasculitis Study Group (FVSG) (2011) The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine 90:19–27CrossRefPubMed Guillevin L, Pagnoux C, Seror R, Mahr A, Mouthon L, Le Toumelin P, French Vasculitis Study Group (FVSG) (2011) The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine 90:19–27CrossRefPubMed
10.
go back to reference Leavitt RY, Fauci AS, Bloch DA, Michel BA, Hunder GG, Arend WP et al (1990) The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis. Arthritis Rheum 33:1101–1107CrossRefPubMed Leavitt RY, Fauci AS, Bloch DA, Michel BA, Hunder GG, Arend WP et al (1990) The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis. Arthritis Rheum 33:1101–1107CrossRefPubMed
11.
go back to reference Hellmich B, Flossmann O, Gross WL, Bacon P, Cohen-Tervaert JW, Guillevin L et al (2007) EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 66:605–617CrossRefPubMedCentralPubMed Hellmich B, Flossmann O, Gross WL, Bacon P, Cohen-Tervaert JW, Guillevin L et al (2007) EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 66:605–617CrossRefPubMedCentralPubMed
12.
go back to reference Rasmussen N, Jayne DRW, Abramowicz D et al (1995) European therapeutic trials in ANCA-associated systemic vasculitis: disease scoring, consensus regimes and proposed clinical trials. European Community Study Group on Clinical Trials in Systemic Vasculitis ECSYS VASTRIAL. Clin Exp Immunol 101(Suppl 1):29–34CrossRef Rasmussen N, Jayne DRW, Abramowicz D et al (1995) European therapeutic trials in ANCA-associated systemic vasculitis: disease scoring, consensus regimes and proposed clinical trials. European Community Study Group on Clinical Trials in Systemic Vasculitis ECSYS VASTRIAL. Clin Exp Immunol 101(Suppl 1):29–34CrossRef
13.
go back to reference Reinhold-Keller E, Beuge N, Latza U, de Groot K, Rudert H, Nölle B et al (2000) An interdisciplinary approach to the care of patients with Wegener’s granulomatosis. Arthritis Rheum 43:1021–1032CrossRefPubMed Reinhold-Keller E, Beuge N, Latza U, de Groot K, Rudert H, Nölle B et al (2000) An interdisciplinary approach to the care of patients with Wegener’s granulomatosis. Arthritis Rheum 43:1021–1032CrossRefPubMed
14.
go back to reference Kuznetsova E, Novikov P, Moiseyev S (2013) Cardiovascular risk in granulomatosis with polyangiitis (Wegener’s) of different severity and duration. Ann Rheum Dis 72(Suppl 3):643CrossRef Kuznetsova E, Novikov P, Moiseyev S (2013) Cardiovascular risk in granulomatosis with polyangiitis (Wegener’s) of different severity and duration. Ann Rheum Dis 72(Suppl 3):643CrossRef
15.
go back to reference Faurschou M, Mellemkjaer L, Sorensen IJ, Svalgaard Thomsen B, Dreyer L, Baslund B (2009) Increased morbidity from ischemic heart disease in patients with Wegener’s granulomatosis. Arthritis Rheum 60:1187–1192CrossRefPubMed Faurschou M, Mellemkjaer L, Sorensen IJ, Svalgaard Thomsen B, Dreyer L, Baslund B (2009) Increased morbidity from ischemic heart disease in patients with Wegener’s granulomatosis. Arthritis Rheum 60:1187–1192CrossRefPubMed
16.
go back to reference Luqmani R, Suppiah R, Edwards CJ, Phillip R, Maskell J, Culliford D et al (2011) Mortality in Wegener’s granulomatosis: a bimodal pattern. Rheumatology 50:697–702CrossRefPubMed Luqmani R, Suppiah R, Edwards CJ, Phillip R, Maskell J, Culliford D et al (2011) Mortality in Wegener’s granulomatosis: a bimodal pattern. Rheumatology 50:697–702CrossRefPubMed
17.
go back to reference Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA et al (2010) Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363:211–220CrossRefPubMed Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA et al (2010) Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363:211–220CrossRefPubMed
18.
go back to reference Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS et al (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363:221–232CrossRefPubMedCentralPubMed Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS et al (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363:221–232CrossRefPubMedCentralPubMed
Metadata
Title
Changing patterns of clinical severity and risk of mortality in granulomatosis with polyangiitis over four decades: the Russian experience
Authors
Pavel I. Novikov
Sergey V. Moiseev
Ekaterina I. Kuznetsova
Eugenia N. Semenkova
Nikolay A. Mukhin
Publication date
01-05-2015
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 5/2015
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-014-3154-4

Other articles of this Issue 5/2015

Rheumatology International 5/2015 Go to the issue

Letter to the Editor - Critique and Appraisal

The lack of efficacy of oxytocin and NSAIDs

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.